Dorsal root ganglion neurons react to semaphorin 3A application through a biphasic response that requires multiple myosin II isoforms.
Growth cone responses to guidance cues provide the basis for neuronal pathfinding. Although many cues have been identified, less is known about how signals are translated into the cytoskeletal rearrangements that steer directional changes during pathfinding. Here we show that the response of dorsal root ganglion (DRG) neurons to Semaphorin 3A gradients can be divided into two steps: growth cone collapse and retraction. Collapse is inhibited by overexpression of myosin IIA or growth on high substrate-bound laminin-1. Inhibition of collapse also prevents retractions; however collapse can occur without retraction. Inhibition of myosin II activity with blebbistatin or by using neurons from myosin IIB knockouts inhibits retraction. Collapse is associated with movement of myosin IIA from the growth cone to the neurite. Myosin IIB redistributes from a broad distribution to the rear of the growth cone and neck of the connecting neurite. High substrate-bound laminin-1 prevents or reverses these changes. This suggests a model for the Sema 3A response that involves loss of growth cone myosin IIA to facilitate actin meshwork instability and collapse, followed by myosin IIB concentration at the rear of the cone and neck region where it associates with actin bundles to drive retraction.
Brown
Jacquelyn A
JA
Department of Anatomy and Neurobiology, Washington University School of Medicine, St. Louis, MO 63110, USA.
Wysolmerski
Robert B
RB
Bridgman
Paul C
PC
D000199:Actins / Q000378:metabolism; D000818:Animals; D005455:Fluorescent Antibody Technique; D005727:Ganglia, Spinal / Q000166:cytology / Q000187:drug effects* / Q000254:growth & development / Q000378:metabolism*; D049452:Green Fluorescent Proteins / Q000378:metabolism; D020439:Growth Cones / Q000187:drug effects / Q000378:metabolism; D007797:Laminin / Q000494:pharmacology; D051379:Mice; D008954:Models, Biological; D024462:Myosin Type II / Q000737:chemistry* / Q000378:metabolism*; D009474:Neurons / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism*; D024507:Nonmuscle Myosin Type IIA / Q000378:metabolism; D024501:Nonmuscle Myosin Type IIB / Q000378:metabolism; D020033:Protein Isoforms / Q000378:metabolism; D011993:Recombinant Fusion Proteins / Q000378:metabolism; D040121:Semaphorin-3A / Q000494:pharmacology*
D000199:Actins; D007797:Laminin; D020033:Protein Isoforms; D011993:Recombinant Fusion Proteins; D040121:Semaphorin-3A; C121346:laminin 1; D049452:Green Fluorescent Proteins; D024462:Myosin Type II; D024507:Nonmuscle Myosin Type IIA; D024501:Nonmuscle Myosin Type IIB